دورية أكاديمية
أعرض في EDS

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.

التفاصيل البيبلوغرافية
العنوان: Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
المؤلفون: Levati L; Laboratory of Molecular Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Bassi C; Department of Translational Medicine, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.; LTTA Center, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy., Mastroeni S; Clinical Epidemiology Unit, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Lupini L; Department of Translational Medicine, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy., Antonini Cappellini GC; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Bonmassar L; Laboratory of Molecular Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Alvino E; Institute of Translational Pharmacology, National Council of Research, Via Fosso del Cavaliere 100, 00133 Rome, Italy., Caporali S; Laboratory of Molecular Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Lacal PM; Laboratory of Molecular Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Narducci MG; Laboratory of Molecular Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Molineris I; Department of Life Science and System Biology, University of Turin, Via Accademia Albertina 13, 10123 Turin, Italy., De Galitiis F; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., Negrini M; Department of Translational Medicine, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.; LTTA Center, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy., Russo G; Laboratory of Molecular Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy., D'Atri S; Laboratory of Molecular Oncology, IDI-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy.
المصدر: Cancers [Cancers (Basel)] 2022 Jul 29; Vol. 14 (15). Date of Electronic Publication: 2022 Jul 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Despite the significant improvements in advanced melanoma therapy, there is still a pressing need for biomarkers that can predict patient response and prognosis, and therefore support rational treatment decisions. Here, we investigated whether circulating miRNAs could be biomarkers of clinical outcomes in patients treated with targeted therapy. Using next-generation sequencing, we profiled plasma miRNAs at baseline and at progression in patients treated with BRAF inhibitors (BRAFi) or BRAFi + MEKi. Selected miRNAs associated with response to therapy were subjected to validation by real-time quantitative RT-PCR. Receiver Operating Characteristics (ROC), Kaplan-Meier and univariate and multivariate Cox regression analyses were performed on the validated miR-1246 and miR-485-3p baseline levels. The median baseline levels of miR-1246 and miR-485-3p were significantly higher and lower, respectively, in the group of patients not responding to therapy (NRs) as compared with the group of responding patients (Rs). In Rs, a trend toward an increase in miR-1246 and a decrease in miR-485-3p was observed at progression. Baseline miR-1246 level and the miR-1246/miR-485-3p ratio showed a good ability to discriminate between Rs and NRs. Poorer PFS and OS were observed in patients with unfavorable levels of at least one miRNA. In multivariate analysis, a low level of miR-485-3p and a high miR-1246/miR-485-3p ratio remained independent negative prognostic factors for PFS, while a high miR-1246/miR-485-3p ratio was associated with an increased risk of mortality, although statistical significance was not reached. Evaluation of miR-1246 and miR-485-3p baseline plasma levels might help clinicians to identify melanoma patients most likely to be unresponsive to targeted therapy or at higher risk for short-term PFS and mortality, thus improving their management.
References: Oncotarget. 2017 Mar 28;8(13):22262-22278. (PMID: 28118616)
Gynecol Oncol. 2015 Sep;138(3):683-8. (PMID: 26074491)
Int J Mol Sci. 2020 Jun 26;21(12):. (PMID: 32604720)
Carcinogenesis. 2017 Oct 1;38(10):966-975. (PMID: 28633434)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Biomolecules. 2018 Apr 26;8(2):. (PMID: 29701682)
J Exp Clin Cancer Res. 2019 Jun 21;38(1):272. (PMID: 31227006)
Front Oncol. 2021 Apr 22;11:608987. (PMID: 33968718)
PLoS One. 2017 Sep 20;12(9):e0184969. (PMID: 28931080)
Front Oncol. 2018 Aug 29;8:327. (PMID: 30211115)
Cancer Res Treat. 2017 Oct;49(4):947-959. (PMID: 28052651)
Int J Mol Med. 2013 Sep;32(3):557-67. (PMID: 23799609)
Cancer Res. 2010 Mar 1;70(5):2115-25. (PMID: 20160041)
Nat Commun. 2018 Feb 22;9(1):771. (PMID: 29472616)
J Clin Invest. 2013 Jan;123(1):285-98. (PMID: 23241961)
N Engl J Med. 2019 Aug 15;381(7):626-636. (PMID: 31166680)
Bratisl Lek Listy. 2020;121(4):302-307. (PMID: 32356447)
Oncogenesis. 2020 Feb 14;9(2):22. (PMID: 32060259)
Cancer. 1950 Jan;3(1):32-5. (PMID: 15405679)
Oncoimmunology. 2020 Feb 26;9(1):1731942. (PMID: 32158624)
J Cell Physiol. 2018 Jul;233(7):5133-5141. (PMID: 29226953)
Front Biosci (Landmark Ed). 2015 Jun 01;20(8):1234-49. (PMID: 25961554)
Acta Derm Venereol. 2016 Jan;96(1):29-34. (PMID: 26039581)
Life Sci. 2021 Mar 1;268:118925. (PMID: 33358903)
Mol Cancer. 2021 Jun 1;20(1):81. (PMID: 34074294)
Cancer Chemother Pharmacol. 2020 Dec;86(6):761-772. (PMID: 33068176)
Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):5979-5987. (PMID: 32572911)
Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991)
Melanoma Res. 2019 Feb;29(1):1-12. (PMID: 30308577)
PLoS One. 2013;8(3):e60134. (PMID: 23527303)
Cells. 2021 Oct 12;10(10):. (PMID: 34685704)
Int J Mol Sci. 2022 Mar 03;23(5):. (PMID: 35269947)
Histol Histopathol. 2022 May;37(5):423-430. (PMID: 34958117)
Pigment Cell Melanoma Res. 2019 Jul;32(4):486-499. (PMID: 30481404)
Target Oncol. 2021 Mar;16(2):197-205. (PMID: 33555543)
Cancers (Basel). 2021 Mar 05;13(5):. (PMID: 33807778)
Cancer Chemother Pharmacol. 2019 Aug;84(2):315-325. (PMID: 31089750)
EBioMedicine. 2021 May;67:103365. (PMID: 33971402)
Sci Rep. 2021 Jul 5;11(1):13502. (PMID: 34226586)
Nat Rev Drug Discov. 2021 Aug;20(8):629-651. (PMID: 34145432)
Cancer Res. 2018 Apr 1;78(7):1833-1844. (PMID: 29437039)
Stat Med. 1985 Jan-Mar;4(1):87-90. (PMID: 3992076)
Cancer Gene Ther. 2021 Dec;28(12):1312-1324. (PMID: 33531648)
Oncol Lett. 2021 Jan;21(1):4. (PMID: 33240410)
Int J Mol Sci. 2017 Nov 07;18(11):. (PMID: 29112174)
Int J Mol Sci. 2020 Jan 29;21(3):. (PMID: 32013263)
PLoS One. 2012;7(1):e30132. (PMID: 22276150)
Eur J Endocrinol. 2020 Jan;182(1):111-121. (PMID: 31721725)
Cancers (Basel). 2018 Aug 16;10(8):. (PMID: 30115848)
Cell. 2018 Mar 22;173(1):20-51. (PMID: 29570994)
Cell. 2019 Nov 14;179(5):1033-1055. (PMID: 31730848)
N Engl J Med. 2012 Oct 4;367(14):1364-5. (PMID: 23034029)
Br J Cancer. 2014 Oct 14;111(8):1572-80. (PMID: 25117811)
Cancers (Basel). 2020 Nov 13;12(11):. (PMID: 33202891)
Clin Chem Lab Med. 2019 Jun 26;57(7):932-953. (PMID: 30838832)
Arch Gynecol Obstet. 2014 Oct;290(4):725-32. (PMID: 24806621)
Anticancer Agents Med Chem. 2022;22(1):152-159. (PMID: 34225636)
Biochem Genet. 2022 Apr;60(2):576-597. (PMID: 34322757)
Int J Mol Sci. 2020 Dec 20;21(24):. (PMID: 33419275)
Future Oncol. 2016 Jan;12(2):175-82. (PMID: 26674983)
NPJ Precis Oncol. 2018 Dec 12;2:28. (PMID: 30564636)
Lancet Oncol. 2016 Dec;17(12):1743-1754. (PMID: 27864013)
Cancers (Basel). 2021 Oct 22;13(21):. (PMID: 34771465)
Front Mol Biosci. 2022 Jan 03;8:771835. (PMID: 35047553)
Cell Physiol Biochem. 2017;44(5):1741-1748. (PMID: 29216623)
Biomolecules. 2021 Nov 08;11(11):. (PMID: 34827646)
DNA Cell Biol. 2018 May;37(5):501-511. (PMID: 29638162)
Cell Res. 2011 Feb;21(2):316-26. (PMID: 20820189)
World J Surg Oncol. 2021 Aug 11;19(1):239. (PMID: 34380511)
Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784. (PMID: 29923435)
Cancer Cell Int. 2020 Jun 16;20:248. (PMID: 32550826)
Cancer Treat Rev. 2015 Jun;41(6):519-26. (PMID: 25944484)
J Invest Dermatol. 2018 Jul;138(7):1609-1619. (PMID: 29408459)
Eur J Cancer. 2021 May;148:61-75. (PMID: 33735811)
Mol Med Rep. 2016 Jan;13(1):273-80. (PMID: 26573378)
Cells. 2020 Feb 11;9(2):. (PMID: 32054078)
Front Cell Dev Biol. 2021 May 31;9:661602. (PMID: 34136482)
Oncotarget. 2017 Apr 11;8(15):24915-24931. (PMID: 28212536)
Am J Cancer Res. 2017 Jun 01;7(6):1350-1371. (PMID: 28670496)
Biochem Biophys Res Commun. 2018 Jun 18;501(1):48-54. (PMID: 29678577)
J Dermatol Sci. 2020 Jan;97(1):77-79. (PMID: 31843231)
Circulation. 2007 Feb 6;115(5):654-7. (PMID: 17283280)
Cancers (Basel). 2021 Jul 02;13(13):. (PMID: 34283053)
Expert Opin Ther Targets. 2015;19(8):1027-35. (PMID: 26156293)
Cell Death Dis. 2016 Mar 24;7:e2159. (PMID: 27010860)
Onco Targets Ther. 2020 Feb 11;13:1245-1253. (PMID: 32103992)
PLoS One. 2018 Nov 6;13(11):e0206942. (PMID: 30399176)
Int J Biol Sci. 2020 Jul 19;16(14):2628-2647. (PMID: 32792861)
Neoplasma. 2021 Mar;68(2):317-324. (PMID: 33231089)
Oncogene. 2014 Oct 30;33(44):5173-82. (PMID: 24166498)
Cell Death Differ. 2019 Jul;26(7):1267-1282. (PMID: 30254376)
Oncotarget. 2016 Jul 26;7(30):47593-47608. (PMID: 27351280)
J Obstet Gynaecol Res. 2021 Mar;47(3):1068-1081. (PMID: 33403756)
Front Oncol. 2021 Dec 01;11:677168. (PMID: 34926237)
RNA Biol. 2019 Jun;16(6):770-784. (PMID: 30806147)
Exp Ther Med. 2019 Jul;18(1):475-482. (PMID: 31258684)
Cancer Lett. 2015 Jun 1;361(2):240-50. (PMID: 25779673)
Int J Cancer. 2013 Jan 15;132(2):E48-57. (PMID: 22907602)
معلومات مُعتمدة: IG 17585 Italian Association for Cancer Research; PE-2016-02364102 Governo Italiano
فهرسة مساهمة: Keywords: BRAF inhibitors; MEK inhibitors; circulating miRNAs; melanoma; resistance
تواريخ الأحداث: Date Created: 20220812 Latest Revision: 20220815
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9367338
DOI: 10.3390/cancers14153706
PMID: 35954369
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14153706